Merit Medical(US:MMSI) ZACKS·2025-04-24 23:05Core Insights - Merit Medical reported revenue of $355.35 million for the quarter ended March 2025, reflecting a year-over-year increase of 9.8% and exceeding the Zacks Consensus Estimate of $352.33 million by 0.86% [1] - The company's EPS for the quarter was $0.86, up from $0.77 in the same quarter last year, resulting in an EPS surprise of 14.67% compared to the consensus estimate of $0.75 [1] Financial Performance Metrics - U.S. sales reached $213.56 million, surpassing the average estimate of $208.66 million by analysts, marking a year-over-year increase of 14.8% [4] - International sales were reported at $141.79 million, slightly below the estimated $143.33 million, with a year-over-year growth of 3.2% [4] - Revenue from Cardiovascular-Peripheral Intervention was $137.28 million, below the average estimate of $141.95 million, showing a 2% increase year-over-year [4] - Cardiovascular-Cardiac Intervention revenue was $99.74 million, exceeding the estimated $98.79 million, with a 10% year-over-year increase [4] - Endoscopy revenue was reported at $16.64 million, below the average estimate of $17.89 million, but reflecting a significant year-over-year increase of 64.2% [4] - Cardiovascular-OEM revenue reached $53.75 million, surpassing the average estimate of $43.84 million, with a year-over-year increase of 36.9% [4] - Total Cardiovascular revenue was $338.71 million, slightly above the estimated $334.45 million, representing an 8.1% year-over-year increase [4] - Revenue from Cardiovascular-Custom Procedural Solutions was $47.94 million, below the average estimate of $49.74 million, indicating a year-over-year decline of 1.8% [4] Stock Performance - Over the past month, Merit Medical's shares have returned -9.6%, compared to a -5.1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]